“Increased Adoption of Moxidectin”
The adoption of moxidectin is growing as it offers a longer-lasting effect compared to ivermectin, which means patients require fewer doses for effective treatment. This trend is leading to improved treatment adherence, as patients are more likely to complete their treatment regimens with less frequent dosing. The extended duration of moxidectin’s effect also contributes to enhanced overall treatment effectiveness, as it reduces the need for regular follow-ups and ensures more consistent results in controlling onchocerciasis.
